VivaGel® Vaginal Gel
VivaGel® is an innovative technology being applied to a range of sexual/women’s health products by Starpharma and its partners, including for treatment & prevention of bacterial vaginosis and prevention of sexually transmitted infections. VivaGel® (SPL7013, or astodrimer sodium) is antiviral and blocks bacteria. It is formulated as a mucoadhesive gel and delivered vaginally. Several clinical studies have successfully tested the safety and efficacy of VivaGel®.
Development Stage:
Clinical – Phase 3 Trial (C3), Registered/ Marketed in Europe, the UK, Australia, New Zealand, South Africa, Singapore, and Indonesia (INT)
Hormonal/Non-Hormonal:
Non-Contraceptive
Delivery Route & Method:
Topical - Gel-Vaginal
Mechanism of Action:
Sulfonated dendrimer providing inhibition of viruses and bacteria; biofilm disruption
Developer:
- Starpharma Pty Limited
Funding:
- Starpharma Pty Limited
Funding Mechanism:
Income from sales; capital raising
Past Funding:
National Institutes of Health (NIH)
Active Ingredient(s):
- SPL7013 (Astodrimer Sodium)
Product Indication(s):
- Bacterial Vaginosis (BV)
- HIV
- HPV
- HSV-2